Ill-fated Contrave trial piles more hurt on Orexigen

Last March, Orexigen ($OREX) landed in hot water with researchers, the FDA and marketing partner Takeda when it blabbed some early trial results that falsely suggested its obesity med could improve cardiovascular outcomes for patients. Just over a year later, it's still facing the consequences. Former FDA deputy commissioner Joshua Sharfstein is calling for U.S. regulators to propose restrictions on the drug, Contrave, to counter the "misleading information" from the California company, Forbes reports. And the FDA has some tools to do that, he noted, including a Risk Evaluation and Mitigation Strategy. More from FiercePharma

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

In a single-arm phase 3b trial, Fasenra helped 62% of nearly 600 patients with severe asthma to go on about their lives without oral corticosteroids.

Forget downbeat biosim predictions. Amgen’s latest quarter shows there’s still plenty of potential in the biosimilars market for a dedicated player.